Questions About Cancer? 1-800-4-CANCER

Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)

Health Professional Version

Changes to This Summary (06/24/2014)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Treatment for Multiple Myeloma

Added text to the evidence listed for tandem autologous bone marrow or peripheral stem cell transplantation and to the evidence listed for high-dose chemotherapy: allogeneic bone marrow or peripheral stem cell transplantation (SCT) to include information about six clinical trials that compared the outcomes of patients receiving tandem autologous transplant to those of patients receiving a reduced-intensity allogeneic SCT after autologous transplant. Also added that patients were assigned to the latter treatments based on the availability of an HLA-matched donor. Added that two meta-analyses of these data showed that although the complete remission rate was higher in patients undergoing reduced-intensity allogeneic SCT, overall survival was comparable because of an increased incidence of nonrelapse mortality with allogeneic transplant (cited Armeson et al. and Kharfan-Dabaja et al. as references 110 and 111, respectively, and level of evidence IiiA).

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.

  • Updated: June 24, 2014